10-Q: Schrdinger, Inc. Reports Strong Q1 2025 Revenue Growth Driven by Software and Drug Discovery Segments
Quarterly Report
Schrdinger, Inc. announces a 63% increase in total revenue for Q1 2025, fueled by growth in both its software and drug discovery segments.
Summary
- Schrdinger, Inc. reported total revenues of $59.6 million for the first quarter of 2025, a 63% increase compared to $36.6 million in Q1 2024.
- Software products and services revenue increased by 46% to $48.8 million, driven by on-premise software, hosted software, and software maintenance.
- Drug discovery revenue saw a significant increase of 237% to $10.7 million, primarily due to the Novartis collaboration.
- The company's net loss for Q1 2025 was $59.8 million, compared to a net loss of $54.7 million in Q1 2024.
- Research and development expenses decreased by 9% to $45.8 million.
- As of March 31, 2025, Schrdinger had cash, cash equivalents, restricted cash, and marketable securities totaling $512.1 million.
- The company believes its current cash resources are sufficient to fund operations for at least the next 24 months.
- Schrdinger is advancing its proprietary drug discovery programs, including SGR-1505, SGR-2921, and SGR-3515, through clinical trials.
- Initial data from the SGR-1505 Phase 1 clinical trial is expected in Q2 2025, and initial data from the SGR-2921 and SGR-3515 Phase 1 clinical trials are expected in the second half of 2025.
Sentiment
Score: 6
Explanation: The document presents a mixed sentiment. Strong revenue growth is positive, but ongoing losses and reliance on collaborations introduce uncertainty. The company's cash position provides stability, but future success depends on clinical trial outcomes and market acceptance.
Positives
- Significant revenue growth in both software and drug discovery segments.
- Strong cash position to fund operations for at least the next 24 months.
- Advancement of proprietary drug discovery programs through clinical trials.
- Successful collaboration with Novartis driving drug discovery revenue.
- Decrease in research and development expenses.
Negatives
- Net loss of $59.8 million for Q1 2025, although this was only a slight increase from the $54.7 million net loss in Q1 2024.
- Reliance on collaborations for drug discovery revenue, which can be unpredictable.
- Limited experience in clinical development as a company.
Risks
- Uncertainty in achieving milestones and generating revenue from drug discovery collaborations.
- Competition in the software and drug discovery markets.
- Potential delays or failures in clinical trials.
- Reliance on third-party manufacturers and CROs.
- Potential for product liability claims.
- Dependence on key personnel.
- Potential for security breaches and data loss.
- Changes in tax laws or their interpretation.
- Potential limitations on the use of NOLs and research and development tax credit carryforwards.
- Risks associated with international operations, including compliance with anti-corruption laws and trade policies.
Future Outlook
Schrdinger anticipates reporting initial data from the SGR-1505 Phase 1 clinical trial in Q2 2025 and initial data from the SGR-2921 and SGR-3515 Phase 1 clinical trials in the second half of 2025. The company believes its existing cash resources are sufficient to fund operations for at least the next 24 months.
Industry Context
The report highlights Schrdinger's position in the competitive molecular discovery and design software market, emphasizing competition from established players and emerging AI-driven approaches. It also notes the importance of the life sciences industry as a key customer base.
Comparison to Industry Standards
- The document does not provide specific comparisons to industry standards or benchmarks.
- It mentions competitors like BIOVIA, Chemical Computing Group, and others, but does not offer a direct comparison of performance metrics.
- The document focuses on Schrdinger's internal performance and collaborations rather than external benchmarks.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation Policy | The non-employee directors of Schrdinger, Inc. (the Company) shall receive the following compensation for their service as members of the Board of Directors (the Board) of the Company. | 2025-04-19 | Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and retain outstanding director candidates and reflects the substantial time commitment necessary to oversee the Companys affairs. |
Related Party Transactions
- The Company paid consulting fees of $109 and $105, respectively, to a member of its board of directors for the three months ended March 31, 2025 and 2024.
- Revenue recognized for services provided by the Company under this grant was $9 and $7, for the three months ended March 31, 2025 and 2024, respectively.
- For the three months ended March 31, 2025 and 2024, the Company recognized $499 and $490, respectively, in drug discovery contribution revenue related to funds received under an agreement with the Bill & Melinda Gates Foundation, aimed at accelerating drug discovery in women's health.
- For the three months ended March 31, 2025 and 2024, the Company recognized $3,844 and zero in software contribution revenue related to funds received under agreements with the Bill & Melinda Gates Foundation to fund the initiative to accelerate the expansion of the Company's computational platform to predict toxicity associated with binding to off-target proteins.
Stakeholder Impact
- Shareholders: The report provides information on the company's financial performance and future prospects, which can influence investment decisions.
- Employees: The company's growth and development plans can impact job security and career opportunities.
- Customers: The report highlights the company's commitment to providing innovative software solutions and advancing drug discovery, which can benefit customers in the life sciences and materials science industries.
- Collaborators: The report provides updates on the company's collaborations and partnerships, which can impact the success of joint projects.
- Creditors: The company's financial stability and cash position can influence its ability to meet its financial obligations.
Next Steps
- Report initial data from the SGR-1505 Phase 1 clinical trial in Q2 2025.
- Report initial data from the SGR-2921 and SGR-3515 Phase 1 clinical trials in the second half of 2025.
- Continue to invest in and develop the computational platform and software solutions.
- Continue research and development efforts for proprietary drug discovery programs.
- Expand software sales to existing customers and increase the customer base.
Key Dates
| Date | Description |
|---|---|
| 2020-11-22 | Date of the exclusive, worldwide collaboration and license agreement with Bristol-Myers Squibb Company (BMS). |
| 2022-06-15 | Effective date of the 2022 Equity Incentive Plan. |
| 2024-02-29 | Date the Company entered into an amended and restated sales agreement with Leerink Partners LLC with respect to an at-the-market offering program (the 'ATM'). |
| 2024-11-11 | Date of the research collaboration and license agreement with Novartis Pharma AG. |
| 2025-03-31 | End of the quarterly period. |
| 2025-04-30 | Date as of which the registrant had 64,212,693 shares of common stock and 9,164,193 shares of limited common stock outstanding. |
| 2025-05-07 | Date of the report. |
Keywords
revenue, drug discovery, software, clinical trials, collaboration, Schrdinger, financial results, milestones, SGR-1505, SGR-2921, SGR-3515, Novartis, BMS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.